Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota
Scutellaria baicalensis Georgi polysaccharide ameliorates DSS-induced ulcerative colitis by improving intestinal barrier function and modulating gut microbiota
复制标题
黄芩多糖通过改善肠道屏障功能及调节肠道菌群，缓解葡聚糖硫酸钠（DSS）诱导的溃疡性结肠炎
DOI：
10.1016/j.ijbiomac.2020.10.259
复制
发表时间：
2021-01-01
影响因子：
8.2
通讯作者：
Feng, Liang
中科院分区：
文献类型：
--
作者：
Cui, Li;Guan, Xueneng;Feng, Liang
本研究旨在探讨黄芩多糖对UC的作用。肠道菌群失调是溃疡性结肠炎的一个世界性问题。从黄芩中分离得到一种均一多糖，命名为SP2 - 1。SP2 - 1由甘露糖、核糖、鼠李糖、葡萄糖醛酸、葡萄糖、木糖、阿拉伯糖、岩藻糖组成，摩尔比为5.06：21.24：1.00：2025：3.49：50.90：228.77：2.40，分子量为3.72 × 10（6）Da。SP2 - 1还抑制促炎细胞因子的水平。此外，由于20 - 1、Occludin和Claudin-5的表达上调，肠屏障得到修复。SP2 - 1显著提高DSS处理小鼠的乙酸、丙酸和丁酸水平。与模型组相比，SP2 - 1处理组厚壁菌门、双歧杆菌、乳杆菌和罗斯拜瑞氏菌的丰度显著增加。SP2 - 1对拟杆菌、变形菌和葡萄球菌的生长有明显的抑制作用。结论：SP2 - 1有可能成为一种新的抗UC候选药物。(C)2020 Elsevier B.V.保留所有权利。
The aim of this study was to investigate the effect of a polysaccharide from Scutellaria baicalensis Georgi on UC. Gut microbiota dysbiosis is a worldwide problem associating with ulcerative colitis. One homogeneous polysaccharide, named SP2-1, was isolated from Scutellaria baicalensis Georgi. SP2-1 comprised mannose, ribose, rhamnose, glucuronic add, glucose, xylose, arabinose, fucose in the molar ratio of 5.06:21.24:1.00:2025:3.49:50.90:228.77:2.40, with Mw of 3.72 x 10(6) Da. SP2-1 treatment attenuated body weight loss, reduced DAI, ameliorated colonic pathological damage, and decreased MPO activity of UC mice induced by DSS. SP2-1 also suppressed the levels of proinflammatory cytokines. Additionally, the intestinal barrier was repaired due to the up-regulated expressions of 20-1, Occludin and Claudin-5. SP2-1 remarkably enhanced the levels of acetic add, propionic acid, and butyric add in DSS-treated mice. Furthermore, as compared with model group, the abundance of Firmicutes, Bifidobacterium, Lactobacillus, and Roseburia were significantly increased with SP2-1 treatment. And SP2-1 could significantly inhibit the levels of Bacteroides, Proteobacteria and Staphylococcus. In conclusion, SP2-1 might serve as a novel drug candidate against UC. (C) 2020 Elsevier B.V. All rights reserved.